Tranexamic Acid Overdose Management
Tranexamic acid overdose should be managed primarily with supportive care, immediate discontinuation of the drug, and aggressive seizure management if neurological symptoms occur, with particular attention to renal function and dose adjustment in patients with renal impairment.
Immediate Management
Discontinue Tranexamic Acid
- Stop all TXA administration immediately upon recognition of overdose 1
- Remove any ongoing infusions
- Document total dose administered and timing
Clinical Manifestations to Monitor
Based on FDA labeling and case reports, overdose symptoms include 1:
Gastrointestinal:
- Nausea, vomiting, diarrhea
Cardiovascular:
- Hypotension (especially orthostatic)
- Cardiac arrhythmias (particularly if inadvertently given intrathecally)
Neurological (Most Critical):
- Seizures (focal or generalized) - most serious complication 1, 2
- Visual impairment or chromatopsia
- Headache
- Mental status changes
- Myoclonus and twitching
- Dizziness
Thromboembolic:
- Deep vein thrombosis
- Pulmonary embolism
- Arterial thrombosis
- Cerebral thrombosis
Dermatologic:
- Rash
- Allergic dermatitis
Specific Management Strategies
Seizure Management
This is the most critical complication requiring immediate intervention 1:
- Administer benzodiazepines as first-line anticonvulsants
- Consider EEG monitoring for patients with myoclonic movements, twitching, or evidence of focal seizures
- Provide standard seizure precautions and airway protection
- Do NOT restart TXA if seizures occur
Renal Considerations
Critical for preventing accumulation and toxicity 1, 2, 3:
TXA is primarily eliminated renally via glomerular filtration. In overdose with renal impairment:
- Assess renal function immediately (serum creatinine, eGFR)
- Consider hemodialysis in severe overdose, particularly in patients with:
- Chronic kidney disease stages 3-5
- Acute kidney injury
- Persistent neurological symptoms
- Serum creatinine >2.83 mg/dL
A case report demonstrated successful management of TXA-induced seizures in a CKD stage 4 patient through drug discontinuation and hemodialysis 2
Cardiovascular Monitoring
- Continuous cardiac monitoring for arrhythmias
- Blood pressure monitoring (watch for hypotension)
- Assess for signs of thromboembolic events
Thromboembolic Risk Assessment
While not typically increased with standard dosing 4, overdose may theoretically increase risk:
- Monitor for signs/symptoms of DVT, PE, stroke
- Consider D-dimer and imaging if clinically indicated
- Do NOT routinely anticoagulate prophylactically unless other indications exist
Supportive Care
Fluid Management
- Intravenous crystalloid for hypotension
- Avoid excessive fluid if concern for cerebral edema from seizures
Symptomatic Treatment
- Antiemetics for nausea/vomiting
- Antihypertensives if needed (though hypotension more common)
Critical Pitfalls to Avoid
Do NOT administer TXA intrathecally - this causes severe seizures and cardiac complications 1
Do NOT ignore renal function - TXA accumulates significantly in renal impairment, and standard doses become toxic 2, 3
Do NOT delay seizure management - TXA-induced seizures require immediate benzodiazepine administration
Do NOT restart TXA after seizures or serious adverse reactions 1
Do NOT give additional pro-thrombotic agents (Factor IX concentrates, hormonal contraceptives) during acute overdose management 1
Monitoring Duration
- Minimum 24 hours observation for neurological symptoms
- Terminal elimination half-life is approximately 2 hours in normal renal function 1
- In renal impairment, TXA concentrations remain elevated for 12+ hours 3
- Extended monitoring (48-72 hours) warranted in severe renal dysfunction
Special Populations
Renal Impairment
Dose-dependent toxicity is dramatically increased 2, 3:
- Even "therapeutic" doses can cause toxicity in CKD stages 3-5
- Consider hemodialysis for symptomatic patients
- TXA is dialyzable
Elderly
- Higher risk due to age-related decline in renal function 1
- Lower threshold for extended monitoring
Documentation
Document clearly:
- Total TXA dose administered
- Time of last dose
- Route of administration (confirm IV, not intrathecal)
- Renal function at presentation
- Any seizure activity or neurological symptoms
- Interventions provided